Several gene signatures were associated with outcomes among patients with advanced clear cell RCC, but not non-clear cell RCC.
Gene signatures were identified as potential predictive biomarkers for outcomes with nivolumab among patients with advanced ccRCC in an analysis of the NIVOREN GETUG-AFU 26 trial.
Circulating tumor DNA analysis of genomic alterations was concordant with tissue genomic analysis in a cohort of patients with advanced RCC.
Atezolizumab plus cabozantinib was tolerable and demonstrated antitumor activity in patients with treatment-naïve, advanced ccRCC, according to a phase 1b study.
Treatment of patients with aRCC who are ineligible for nephrectomy with nivolumab plus ipilimumab improved outcomes compared with sunitinib, in a post hoc analysis of CheckMate 214.
Gene signatures were associated with response rate to nivolumab plus ipilimumab among patients with ccRCC, according to results of a phase 2 trial.